1) Jacobsen S, Sonne-Holm S, Rovsing H, et al. Degenerative lumbar spondylolisthesis:an epidemiological perspective:the Copenhagen osteoarthritis study. Spine (Phila Pa 1976) 2007;32(1):120-5.
2) Lee CW, Yoon KJ, Ha SS. Which approach is advantageous to preventing the development of adjacent segment disease? Comparative analysis of 3 different lumbar interbody fusion techniques (ALIF, LLIF, and PLIF) in L4-5 spondylolisthesis. World Neurosurg 2017;105:612-22.
3) Derman PB, Albert TJ. Interbody fusion techniques in the surgical management of degenerative lumbar spondylolisthesis. Curr Rev Musculoskelet Med 2017;10(4):530-8.
4) Campbell PG, Nunley PD, Cavanaugh D, et al. Short-term outcomes of lateral lumbar interbody fusion without decompression for the treatment of symptomatic degenerative spondylolisthesis at L4-5. Neurosurg Focus 2018;44(1):E6.
5) Isaacs RE, Sembrano JN, Tohmeh AG. SOLAS Degenerative Study Group:Two-year comparative outcomes of MIS lateral and MIS transforaminalinterbody fusion in the treatment of degenerative spondylolisthesis:PartII:radiographic findings. Spine (Phila Pa 1976) 2016;41 Suppl 8:S133-44.
6) Lee CW, Yoon KJ, Ha SS. Which approach is advantageous to preventing development of adjacent segment disease? Comparative analysis of 3 different lumbar interbody fusion techniques (ALIF, LLIF, and PLIF) in L4-5 spondylolisthesis. World Neurosurg 2017;105:612-22.
7) Weinstein MC, Torrance G, McGuire A. QALYs:the basics. Value Health 2009;12 Suppl 1:S5-9.
8) Fischer CR, Cassilly R, Dyrszka M, et al. Cost-effectiveness of lumbar spondylolisthesis surgery at 2-year follow-up. Spine Deform 2016;4(1):48-54.